NLRC4 and hematoma: Such data indicate that determination of serum NLRC4, which is identified as an inflammatory biomarker, may be in clinical use for objectification of ICH patients' state and, along with NIHSS scores and hematoma volume, may be allowed to efficiently predict functional outcome after ICH onset.